Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6461382 | 0.87 | MAPK1 (0.45) | GAAKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL8106855 | 0.85 | KMT2A (0.52) | GAAKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL29549457 | 0.84 | KMT2A (0.43) | GAAKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL27432088 | 0.84 | KMT2A (0.46) | GAAKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL29613534 | 0.84 | TSHR (0.44) | GAAKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL24510725 | 0.84 | TSHR (0.44) | GAAKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL2246779 | 0.84 | KMT2A (0.43) | GAAKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL2250394 | 0.81 | ALDH1A1 (0.40) | GAAKDM4EALDH1A1KMT2AHTT | |
| Methyl 2,3-Dimethoxybenzoate SCHEMBL311487 | 0.80 | GAA (0.66) | GAAKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL13117403 | 0.80 | KMT2A (0.42) | KDM4EKMT2AHTTTSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | Design Therapeutics, Inc. | 2024-05-23 | — | — | US | disclosed |
| CN-117279636-A | Methods and compounds for modulating myotonic muscular dystrophy type 1 | 设计治疗公司 | 2023-12-22 | — | — | CN | disclosed |
| EP-4259133-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022126000-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022126000-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-6001561-A | AN ANALYTE-SPECIFIC BINDING MEMBER CONJUGATED TO A CHEMILUMINESCENT COMPOUND; FOR SENSITIVE AND ACCURATE ANALYSIS AND FOR CONTROLLING TIMING OF LUMINESCENT REACTION | ABBOTT LABORATORIES (US) | 1999-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | MTPN, DMPK, MBNL1 | GAA 2014/4885KDM4E 1761/4885ALDH1A1 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.